Bicara Therapeutics Inc.

NasdaqGM:BCAX Stock Report

Market Cap: US$1.8b

Bicara Therapeutics Management

Management criteria checks 3/4

Bicara Therapeutics' CEO is Claire Mazumdar Clemon, appointed in Jan 2020, has a tenure of 6.5 years. total yearly compensation is $927.69K, comprised of 67.4% salary and 32.6% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $10.18M. The average tenure of the management team and the board of directors is 3.5 years and 2.8 years respectively.

Key information

Claire Mazumdar Clemon

Chief executive officer

US$927.7k

Total compensation

CEO salary percentage67.37%
CEO tenure6.5yrs
CEO ownership0.6%
Management average tenure3.5yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

New Narrative • Apr 16

Phase III Progress In Head And Neck Cancer Will Reshape Long Term Outlook

Catalysts About Bicara Therapeutics Bicara Therapeutics is a clinical stage biotech company developing bifunctional antibodies for targeted tumor modulation, with a focus on its lead asset FICERA in HPV negative head and neck cancer. What are the underlying business or industry changes driving this perspective?
New Narrative • Apr 02

Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer

Catalysts About Bicara Therapeutics Bicara Therapeutics is a clinical stage biotech company focused on bifunctional antibodies for targeted tumor modulation, led by its FICERA program in HPV negative head and neck cancer. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • Mar 31

Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement

Summary Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-HN01 study for 1st-line R/M HPV-negative HNSCC. BCAX's ficerafusp alfa plus KEYTRUDA achieved a 12-month OS of 61% and a confirmed ORR of 54% in phase 1/1b, supporting continued development. Key upcoming catalysts for BCAX include phase 3 interim data in mid-2027 and long-term phase 1b follow-up at ASCO 2026, with near-full enrollment expected by year-end. BCAX is well-capitalized, with more than $414.8M in cash and funding runway into H1 2029, but faces competitive risk from Genmab’s petosemtamab and trial readouts. Read the full article on Seeking Alpha
Analysis Article • Jul 15

We're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Apr 19

Bicara: Innovative Precision Tumor Targeting

Summary Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial health is robust, with $489.7 million in cash, ensuring operations through mid-2029, bolstered by a successful IPO and Series C funding. Early clinical data for ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC shows significant antitumor activity and manageable safety, supporting its potential market impact. Bicara's pivotal Phase 2/3 trial could establish ficerafusp alfa as a new standard of care, with a potential market revenue of $1.3 billion annually. Read the full article on Seeking Alpha
Analysis Article • Mar 13

We Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 02

Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me

Summary Bicara Therapeutics is a new biotech firm focusing on innovative cancer treatments, currently advancing its lead candidate, ficerafusp alfa, targeting challenging cancers like HNSCC. BCAX's financial health is strong, with sufficient capital to fund operations for about four years, but relies heavily on the success of ficerafusp alfa. Early trial results for ficerafusp alfa show promise, particularly in HPV-negative HNSCC, but the lack of diverse pipeline and early-stage data pose significant risks. Given the long wait for potential approval and high volatility, BCAX is a speculative investment better suited for patient, risk-tolerant investors, and I would personally watch for a favorable entry point. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Claire Mazumdar Clemon's remuneration changed compared to Bicara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$157m

Dec 31 2025US$928kUS$625k

-US$138m

Sep 30 2025n/an/a

-US$122m

Jun 30 2025n/an/a

-US$103m

Mar 31 2025n/an/a

-US$92m

Dec 31 2024US$9mUS$518k

-US$68m

Sep 30 2024n/an/a

-US$59m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$5mUS$450k

-US$52m

Compensation vs Market: Claire's total compensation ($USD927.69K) is below average for companies of similar size in the US market ($USD5.19M).

Compensation vs Earnings: Claire's compensation has been consistent with company performance over the past year.

CEO

Claire Mazumdar Clemon (36 yo)

6.5yrs
Tenure
US$927,688
Compensation

Dr. Claire Mazumdar Clemon, PhD, M.B.A., serves as Director of Noora Health and is Director at Relay Therapeutics, Inc. since June 09, 2025. She serves as Chief Executive Officer and Director of Bicara The...

Leadership Team

NamePositionTenureCompensationOwnership
Claire Mazumdar Clemon
CEO & Director6.5yrsUS$927.69k0.55%
$ 10.2m
Ryan Cohlhepp
President5.8yrsUS$858.40k0.28%
$ 5.1m
Ivan Hyep
CFO & Treasurer5.3yrsUS$3.60m0.20%
$ 3.6m
Rachel Frank
Vice President of Investor Relations and Corporate Communicationsno datano datano data
Lara Meisner
Chief Legal Officer2.7yrsno datano data
Pauline Dufresne
Chief People Officerno datano datano data
Rachel Salazar
SVP of R&D Strategy and Operationsno datano datano data
Sathish Hasige
Senior VP and Head of Technical Operations & Supply Chain3.5yrsno datano data
Angela Windt
VP & Head of Regulatory Affairs3.5yrsno datano data
Jeltje Schulten
Senior Vice President of Clinical & Medical Affairs2.3yrsno datano data
Jean-Paul Rodrique
Senior VP & Global Head of Quality Assuranceno datano datano data
Jenna Cohen
Chief Corporate Affairs Officerno datano datano data
3.5yrs
Average Tenure
45yo
Average Age

Experienced Management: BCAX's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Claire Mazumdar Clemon
CEO & Director6.5yrsUS$927.69k0.55%
$ 10.2m
Ryan Cohlhepp
President2.5yrsUS$858.40k0.28%
$ 5.1m
Michael Powell
Independent Chairman of the Board1.9yrsUS$296.13k0%
$ 0
Anders Hove
Board Observerno datano datano data
Kiran Mazumdar-Shaw
Independent Director7.6yrsUS$252.63k0.68%
$ 12.6m
Scott Robertson
Independent Director2.8yrsUS$263.63k0%
$ 0
Ketan Patel
Board Observerno datano datano data
Jason Fuller
Board Observer3.5yrsno datano data
Kathryn Haviland
Independent Director2.8yrsUS$253.63k0.011%
$ 209.0k
Jonathan Edwards
Board Observerno datano datano data
Carolyn Ng
Non-Executive Independent Director2.6yrsno datano data
Jake Simson
Non Executive Independent Director3.3yrsUS$252.63k0%
$ 0
2.8yrs
Average Tenure
49yo
Average Age

Experienced Board: BCAX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/15 23:38
End of Day Share Price 2026/07/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bicara Therapeutics Inc. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Suranjit MukherjeeBTIG
Eric SchmidtCantor Fitzgerald & Co.